Capricor Therapeutics (CAPR) Operating Income: 2011-2025
Historic Operating Income for Capricor Therapeutics (CAPR) over the last 13 years, with Sep 2025 value amounting to -$26.3 million.
- Capricor Therapeutics' Operating Income fell 102.03% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.0 million, marking a year-over-year decrease of 99.11%. This contributed to the annual value of -$42.6 million for FY2024, which is 76.78% down from last year.
- According to the latest figures from Q3 2025, Capricor Therapeutics' Operating Income is -$26.3 million, which was down 5.21% from -$25.0 million recorded in Q2 2025.
- Capricor Therapeutics' 5-year Operating Income high stood at -$1.3 million for Q4 2023, and its period low was -$26.3 million during Q3 2025.
- Moreover, its 3-year median value for Operating Income was -$9.2 million (2023), whereas its average is -$11.8 million.
- In the last 5 years, Capricor Therapeutics' Operating Income skyrocketed by 84.12% in 2023 and then crashed by 500.79% in 2024.
- Quarterly analysis of 5 years shows Capricor Therapeutics' Operating Income stood at -$6.4 million in 2021, then dropped by 26.44% to -$8.1 million in 2022, then soared by 84.12% to -$1.3 million in 2023, then slumped by 500.79% to -$7.7 million in 2024, then plummeted by 102.03% to -$26.3 million in 2025.
- Its Operating Income was -$26.3 million in Q3 2025, compared to -$25.0 million in Q2 2025 and -$7.7 million in Q4 2024.